Amgen's Repatha lowered first heart attacks and strokes by 36% in a major trial, suggesting PCSK9 drugs may prevent acute ...
Amgen cholesterol drug cuts risk of first cardiac event by 25% Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback